Measure What Matters May 7, 2020 Applying an FDA lens to your business Sparta Systems recently met with key leadership at FDA Center for Drug Evaluation and Research (CDER), Center for Device and Radiological Health (CDRH) and the Office of Regulatory Affairs (ORA) to discuss quality trends affecting pharmaceutical, biologics and medical device manufacturers. Based on those meetings, we’ve developed a series of reports on quality, technology and legislation. Medical product manufacturing companies are required to compile and use quality metrics to assess the quality, safety and efficacy of their sites and products. However, such metrics do not currently need to be routinely reported to the FDA. Such routine reporting was proposed in 2016 in the FDA’s Draft Guidance on Quality Metrics. Based on the effort required to implement the necessary reporting measures at that time, many in the life sciences industry challenged the proposal. To date, the reporting requirement has not been implemented—but that doesn’t mean it’s been shelved permanently. In fact, the idea of submitting quality metrics is still very top-of-mind to senior CDER leadership. Changing Times Certain quality metrics enable more effective risk-based decision-making. The FDA already requests and reviews such metrics during inspections. But without regular reporting, the agency is unable to create a database that normalizes the metrics and associates certain rates with “quality maturity.” Such a framework would provide the FDA a way to inform its risk-based Site Selection Program. As a result, the agency could prioritize inspections of sites where metrics indicated higher risk and reduce the rate of inspection of low-risk sites, saving time and money for both the agency and compliant sites. Companies that document and submit good performance metrics may be audited less often (or perhaps only “virtually” in light of COVID-19), saving critical operating dollars and a significant amount of staff time. This ability to prioritize is more important than ever. The volume of manufacturing, packaging, and distribution sites has expanded. And the emergence of COVID-19 makes in-person site inspections more onerous than ever. The FDA needs quality data to prioritize its “to do” list—as do the manufacturers that collect that data. And as many companies now electronically collect quality data, submitting reports is easier than it was four years ago. While the metrics guidelines are still being finalized, preparation should be taken to assure that you aren’t left behind. We suggest that manufacturers prepare now, while the guidelines are being finalized. Important Metrics If the FDA implements annual reporting according to its original guidance, reports will be required by product application, which might cover multiple sites. The FDA will use the data to compile a Risk Profile Aggregate for all products made at a site, then prioritize audits according to those profiles. The most-likely quality metrics for the FDA to require are: Lot Acceptance Rates (LAR)Calculated: The number of accepted lots divided by the number of lots started.Why? To measure process performance.What It Means: LAR provides insight into manufacturing efficiency and process quality. Batches or processes are started but not completed, either due to equipment failure or scheduling mix-ups and exceeded hold times, may indicate poor or inadequate manufacturing operations support infrastructure.Product Quality Complaint Rates (PQCR)Calculated: The number of quality complaints received for a product, divided by the total number of units or doses distributed.Why? To assess patient and customer outcomes.What It Means: PQCR is a general indicator of product quality with respect to label claims and patient perception. While there are many valid reasons for a manufacturer to be skeptical of some product quality complaints, a volume of related complaint may indicate an underlying issue that warrants response.Invalidated Out-of-Specification Rates (IOOSR or OOS)Calculated: The ratio of invalidated OOS test results for lot release compared to the total number of OOS test results (valid and invalidated).Why? An indicator of lab operations.What It Means: The process of invalidating any result is risky because it necessarily involves trusting one set of results over another. Even if the reasoning is scientifically defensible and valid, frequent instances of invalidated OOS results will raise questions either into the reliability or the suitability of lab operations. You can see how these metrics could help the FDA prioritize audits. But there’s another reason to establish a reporting routine for these metrics: Regardless of FDA requirements, they can help you prioritize your own quality “to-do” list. Prioritize Quality, Not Just Compliance To report these metrics effectively and efficiently, you need to be able to capture, calculate, trend and electronically submit the related quality data. You also need to demonstrate how the metrics affect performance. Quality teams that are already collecting and configuring data digitally are a step ahead, but even they have some work to do.To prepare: Configure the specified measurements in your quality management system (QMS) and production processes. Remember to collect each metric by site/location.Create metrics dashboards or reports that are easy to understand and drill down into.Make sure reporting is adaptable based on timeframe, site and other variables that affect performance (e.g., processes, equipment, personnel). Determine how you will share quality metrics externally. For example, you could set up report to run on demand as well as on an automated schedule, or you could share dashboards with permitted users. While it may take some upfront effort to collect these measurements and configure reporting, the insights they provide can lead to notable savings and other benefits. The potential to reduce the likelihood of inspections alone can produce significant savings in time and resources. This time around, the FDA may not be asking for too much. It could be nudging life sciences companies toward a quality win-win. After all, manufacturers can—and should—continually improve performance. The benefits of doing so can quickly cascade across your organization. Measuring, trending and regularly reviewing these quality metrics provide a clear path for doing so. Share via: Twitter LinkedIn Facebook Email
WEBINAR AI-Driven Innovation: Redefining Quality Management in Life Sciences Take a deep dive into the confluence of AI and life sciences, exploring how artificial intelligence is poised to revolutionize the realm of quality management in the sector. Learn more
EVENT 9th GCC Regulatory Affairs Pharma Summit (and Quality Conference) 2024 GCC Regulatory Affairs Pharma Summit is an annual event that provides platform for pharmaceutical regulatory experts and industry professionals in the GCC region to share insights and discuss about the latest updates in the pharmaceutical regulations. We are Gold Sponsors of the 9th GCC Regulatory Affairs Pharma Summit 2024. Learn more
EVENT Honeywell Life Sciences Innovation Days Honeywell invites you to join us for one of our Life Sciences Innovation Days, a series offered throughout the globe in 2024. We will present a variety of process innovations to support the digital transformation of life sciences manufacturing. Themes will include orchestrating systems and data, preventing and containing cyber incidents, quality control and management, modular automation, and the Honeywell life sciences roadmap. Discussion will address streamlining manufacturing, creating batch records, and fulfilling regulatory reporting requirements. Learn more
EVENT Pharma Manufacturing World Summit Join us at Pharma Manufacturing World Summit on May 14, 2024 where Honeywell's Zillery Fortner will be co-presenting on "The Value of a Unified Life Sciences Solution in Pharma 4.0." Learn more
EVENT TUG Europe Join industry peers at one of these FREE events for TrackWise and TrackWise Digital customers, with two dates and locations to choose from. Enjoy a networking at our pre-event receptions, as we celebrate 30 years of TrackWise! Take advantage of a FREE TrackWise Digital pre-event training workshop. Learn more
EVENT RQA 2024: International QA Conference With diverse industry representation including regulatory authorities like the MHRA, it’s a hotspot for those in GCP, GLP, GMP, pharmacovigilance, and more. The conference has evolved to cover a wider scope, offering unparalleled networking opportunities across three dynamic days for delegates, sponsors, and exhibitors to engage on pivotal industry topics. Register to attend this insightful event where you can hear our Industry Business Development Director, Fabrizio Mangilio deliver one of this year's RQA 2024 keynote sessions. We are Platinum Sponsors of the RQA 2024: International QA Conference Learn more
EBOOK 5 Things to Know About EUDAMED EUDAMED (European database for medical devices) is a centralized database that aims to enhance the transparency and traceability of medical devices in the EU. Learn more
WEBINAR EUDAMED 2024 and Beyond: Preparing for the Future of Medical Device Oversight Watch our on-demand webinar and gain valuable insights into the transformative impact of EUDAMED on the Medical Device industry. Learn more
WHITE PAPER Future-Proofing a Pharma Manufacturing Legacy through Digital Quality Transformation As industries adopt technological advances and rapidly move into the fourth industrial revolution, it is essential to assess the impact of these isolated data pockets on the workforce, customers and the safety of patients. Learn more
WEBINAR Transforming Quality Operations in the Digital Age Learn how Orion is using TrackWise Digital® to transform quality operations and enhance traceability among suppliers to continuously improve quality and patient safety. Learn more
ON-DEMAND Quality Risk Management for the Pharmaceutical Industry An Introduction to TrackWise Digital® Quality Risk Management (QRM) for the Pharmaceutical Industry. Learn more
CASE STUDY Simplicity at the Forefront: Meitheal Pharmaceuticals Case Study Meitheal Pharmaceuticals Transforms Document and Training Management with TrackWise Digital® Learn more
EVENT Building a Winning Life Science Eco-system – Leveraging the Quality Link between Platform, Processes and Patients Watch this unique webinar to discover how Life Science organizations can a combine a best-in-class platform with freedom of solution choice to improve product quality, productivity, and supply chain continuity. Learn more
CASE STUDY Empowering Innovation: Revelle Aesthetics Transforms Document Management and Training with TrackWise Digital Revelle Aesthetics selected TrackWise Digital to manage its key quality management processes—document management and training management. Learn more